Lincoln National Corp Cel Sci Corp Transaction History

Lincoln National Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$1.63 - $3.08 $45,966 - $86,856	28,200 Added 32.4%	115,245 $220,000
Q4 2023 Feb 06, 2024	BUY	$1.07 - $3.07 $33,705 - $96,705	31,500 Added 56.71%	87,045 $236,000
Q3 2023 Nov 03, 2023	BUY	$1.17 - $2.86 $37,703 - $92,163	32,225 Added 138.19%	55,545 $69,000
Q2 2023 Aug 04, 2023	BUY	$2.11 - $2.83 $22,418 - $30,068	10,625 Added 83.69%	23,320 $56,000
Q1 2023 May 01, 2023	SELL	$2.17 - $3.13 $5,642 - $8,138	-2,600 Reduced 17.0%	12,695 $29,000
Q4 2022 Feb 07, 2023	BUY	$1.99 - $3.52 $1,194 - $2,112	600 Added 4.08%	15,295 $35,000
Q1 2022 May 09, 2022	BUY	$3.93 - $7.7 $17,488 - $34,265	4,450 Added 43.44%	14,695 $58,000
Q3 2021 Nov 05, 2021	BUY	$7.64 - $12.49 $78,271 - $127,960	10,245 New	10,245 $113,000
Q1 2020 Apr 24, 2020	SELL	$7.54 - $17.05 $98,261 - $222,195	-13,032 Closed	0 $0
Q3 2019 Nov 06, 2019	BUY	$6.0 - $9.6 $78,192 - $125,107	13,032 New	13,032 $117,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.